DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, which reached $1.114 billion, slightly exceeding analysts' expectations of $1.112 billion. However, the company's Non-GAAP earnings per share (EPS) were $0.45, which fell short of the forecasted $0.50. The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating incomes. Despite these mixed results, DexCom's revenue trajectory indicates ongoing expansion, especially in international markets.
| Metric | Q4 2024 | Q4 Estimate | Q4 2023 | Y/Y Change |
|---|---|---|---|---|
| EPS (Non-GAAP) | $0.45 | $0.50 | $0.50 | -10.0% |
| Revenue | $1.114B | $1.112B | $1.035B | +8.0% |
| Operating Income (Non-GAAP) | $209.5M | N/A | $242.7M | -13.7% |
| Gross Profit Margin (Non-GAAP) | 59.4% | N/A | 64.2% | -4.8 pp |
Source: Analyst estimates for the quarter provided by FactSet.
An Overview of DexCom's Business
DexCom specializes in continuous glucose monitoring systems, primarily focusing on individuals managing diabetes. Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose level tracking, giving users actionable insights. The company has been concentrating on product development, aiming to refine and expand its offerings with advances in technology such as artificial intelligence. DexCom’s growth hinges on innovation, regulatory approvals, and broadening its market reach domestically and internationally.
Recent areas of focus include the introduction of their G7 system and further development of offerings like the Dexcom Stelo, targeting non-insulin-using diabetes patients.
Quarterly Highlights: Financial and Strategic Insights
During Q4 2024, DexCom reported $1.114 billion in revenue, marking an 8% increase from the previous year. This revenue jump was slightly above analyst expectations, supported by a significant 17% growth in international revenue, driven by market expansions and product adoptions. Conversely, the Non-GAAP operating income dropped 13.7% to $209.5 million, and the Non-GAAP EPS of $0.45 indicated a 10% year-over-year decline, underscoring operational and cost challenges faced by the company.
The quarter featured significant strategic moves, including the submission of the Dexcom G7 15-day CGM system to the FDA. This product is expected to enhance their offerings through improved usability and accuracy, setting the stage for future market penetration. Additionally, the company furthered its innovative trajectory with new AI-driven glucose monitoring capabilities and the launch of Stelo, expanding their reach to broader diabetes management applications.
Reimbursement achievements were notable, such as the Dexcom ONE+ gaining coverage in France for patients with type 2 diabetes on basal insulin. International revenue saw a 19% organic growth increase, highlighting successful footprint expansion beyond the U.S. A strategic partnership with ŌURA was also announced, aiming to integrate Dexcom's glucose data into a larger health management ecosystem, potentially broadening user engagement and long-term market opportunities.
However, challenges persisted with narrower gross and operating margins. The gross profit margin fell by 4.8 percentage points. .
The Road Ahead
Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a Non-GAAP operating margin goal of around 21%. The approval and expected release of the G7 15-day system in the U.S. is a key milestone anticipated to bolster future performance and competition stance.
Investors should monitor the regulatory developments surrounding key products like the G7 and market adoption rates, especially with the increasing integration of AI-driven features.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 932% — a market-crushing outperformance compared to 176% for the S&P 500.*
They just revealed what they believe are the 10 best stocks for investors to buy right now…
*Stock Advisor returns as of February 7, 2025
JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic, long January 2027 $65 calls on DexCom, short January 2026 $85 calls on Medtronic, and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
